At 7.5% CAGR, the North America Immunodiagnostics Market is Projected to be worth US$ 17,399.10 million by 2030, says Business Market Insights

According to Business Market Insights research, the North America immunodiagnostics market was valued at US$ 10,463.48 million in 2023 and is expected to reach US$ 17,399.10 million by 2030, registering a CAGR of 7.5% from 2023 to 2030. Increasing prevalence of infectious diseases and growing use of point-of-care immunodiagnostics are the critical factors attributed to the North America immunodiagnostics market expansion.

The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostics tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests.

Human immunodeficiency virus (HIV) continues to be a major public health issue worldwide. In 2021, there were ~38.4 million people worldwide with HIV, as per the Joint United Nations Programme on HIV/AIDS (UNAIDS). Besides, hepatitis is another major factor driving the immunodiagnostics market. According to the World Health Organization (WHO), nearly 58 million people worldwide suffer from chronic hepatitis C infection, with 1.5 million new conditions occurring yearly. Furthermore, about 3.2 million adolescents and children have hepatitis C infection. Approved by all member states, the global hepatitis WHO strategy aims to reduce new hepatitis infections by 90% and mortalities by 65% during 2016–2030. Such global initiatives are fueling the demand for immunodiagnostics products.

Further, tuberculosis (TB), COVID-19, and other hospital-acquired infections (HAIs) require immunodiagnostics tests.

• TB has been the 13th leading cause of death and the second-leading infectious killer after COVID-19. In 2020, 1.5 million people died from TB and affected an estimated 10 million people, comprising 5.6 million males, 3.3 million females, and 1.1 million children globally.

• In 2021, a total of 7,860 TB cases were reported to CDC's National Tuberculosis Surveillance System (NTSS) by the 50 states of America and the District of Columbia (DC).

• According to Worldometer, millions of deaths were reported worldwide due to the COVID-19 pandemic. It strained healthcare systems and increased the need for immunodiagnostics tests.

Diagnostics play a vital role in determining suitable medical treatments. Immunodiagnostics help diagnose diseases that severely impact the immune system. Hence, the rising prevalence of infectious diseases lead to the surging demand for immunodiagnostics products.  

On the contrary, inadequate reimbursement scenario hurdles the growth of North America immunodiagnostics market.

Based on product, the North America immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.5% share of North America immunodiagnostics market in 2023, amassing US$ 5,812.20 million. It is projected to garner US$ 9,554.62 million by 2030 to expand at 7.4% CAGR during 2023–2030. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the North America immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment held 44.4% share of North America immunodiagnostics market in 2023, amassing US$ 4,647.55 million. It is projected to garner US$ 8,021.81 million by 2030 to expand at 8.1% CAGR during 2023–2030. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the North America immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. The hospitals segment held 43.6% share of North America immunodiagnostics market in 2023, amassing US$ 4,561.04 million. It is projected to garner US$ 7,477.59 million by 2030 to expand at 7.3% CAGR during 2023–2030.  

Based on country, the North America immunodiagnostics market is segmented into the US, Canada, Mexico. Our regional analysis states that the US captured 84.7% share of North America immunodiagnostics market in 2023. It was assessed at US$ 8,858.38 million in 2023 and is likely to hit US$ 14,596.10 million by 2030, exhibiting a CAGR of 7.4% during 2023–2030.  

Key players operating in the North America immunodiagnostics market are Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com